Providers

Jan 23, 2026

AL Cardiac Amyloidosis Presenting as Grade 3 ATTR Mimicry on Scintigraphy

Jan 10, 2026

Cardiac Amyloidosis (ATTR-CM) Online Support Group

Dec 26, 2025

Screening for transthyretin amyloid cardiomyopathy in patients with musculoskeletal symptoms: Red flags in the rheumatology/orthopedics practice setting

Sep 11, 2019

Matt Millen Featured In Episode Of ‘The B1G Story’

BridgeBio

Alnylam® Pharmaceuticals

Giada Bianchi, MD

Hereditary amyloidosis in Brazil: a focus on access to diagnosis and treatment

Paula Schmitt

Amyloidosis, A Tricky Diagnosis, Can Be Traced to Vietnam and Exposure to Agent Orange

1
2
3
4
5
6
7
8
9
…
Next page
Last page

Subscribe to

Newsletter

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion